گزارش یک مورد C3 Glomerulopathy

Authors

  • آقائی, نیره کارشناس ارشد پرستاری، مربی دانشکده پرستاری مامایی نسیبه ساری، دانشگاه علوم پزشکی مازندران، ایران
  • عابدی سماکوش, محمد فوق تخصص نفرولوژی ، استادیارگروه داخلی ،دانشکده پزشکی ساری، دانشگاه علوم پزشکی مازندران، ایران
  • محمودی, بابک دستیار گروه داخلی، دانشکده پزشکی - دانشگاه علوم پزشکی مازندران- ساری، ایران
  • پاکدل, لیلا فوق تخصص روماتولوژی،استادیارگروه داخلی ،دانشکده پزشکی ساری، دانشگاه علوم پزشکی مازندران، ایران
Abstract:

Complement component 3 glomerulopathy (C3G) defines a group of newly classified disorders that is due to C3 deposition in glomeruli. Very few outbreaks of this disease have been reported in the world. In this study, a 56 year old woman is reported who had complaints of weakness, abdominal pain, and skin petechiae and purpura. Laboratory tests revealed mild anemia and high serum creatinine level. Complementary studies were performed and the patient was suspected of having some form of vasculitis, especially PAN and Henoch Schonlein. Negative differential diagnosis of the most common reviews were obtained and due to lack of response to conventional therapy including corticosteroids and endoksan, kidney biopsy was done to detect the diagnosis. The patient was diagnosed with C3G. She had loss of consciousness, severe anemia, and rectorhalgia and transferred to Intensive Care Unit but died despite therapeutic efforts.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

C3 glomerulopathy

C3 glomerulopathy is a recently defined entity that encompasses a group of kidney diseases caused by abnormal control of complement activation with deposition of complement component C3 in glomeruli leading to variable glomerular inflammation. Before the recognition of the unique pathogenesis of these cases, they were variably classified according to their morphological features. C3 glomerulopa...

full text

گزارش یک مورد c۳ glomerulopathy

گلومرولوپاتی گروه جدیداً طبقه بندی شده از اختلالات ناشی از رسوب c3 در گلومرول ها می باشد که تاکنون تعداد بسیار معدودی از این بیماری در دنیا گزارش شده است. در این مطالعه، خانم 56 ساله ای با شکایت ضعف، درد شکم و ضایعات پوستی پتشی و پورپورا تحت بررسی قرار گرفت. در بررسی های آزمایشگاهی، کراتینین بالا و آنمی خفیف مشاهده شد. بیمار با شک به ابتلا به نوعی واسکولیت، به خصوص pan و هنوخ شوئن لاین تحت بررسی...

full text

C3 glomerulopathy: consensus report

C3 glomerulopathy is a recently introduced pathological entity whose original definition was glomerular pathology characterized by C3 accumulation with absent or scanty immunoglobulin deposition. In August 2012, an invited group of experts (comprising the authors of this document) in renal pathology, nephrology, complement biology, and complement therapeutics met to discuss C3 glomerulopathy in...

full text

Overview of C3 Glomerulopathy

C3 glomerulopathy is an umbrella term, which includes several rare forms of glomerulonephritis (GN) with underlying defects in the alternate complement cascade. A common histological feature noted in all these GN is dominant C3 deposition in the glomerulus. In this review, we will provide an overview of the complement system as well as mediators, with an introduction to pharmaceutical agents th...

full text

Recent insights into C3 glomerulopathy

'C3 glomerulopathy' is a recent disease classification comprising several rare types of glomerulonephritis (GN), including dense deposit disease (DDD), C3 glomerulonephritis (C3GN) and CFHR5 nephropathy. These disorders share the key histological feature of isolated complement C3 deposits in the glomerulus. A common aetiology involving dysregulation of the alternative pathway (AP) of complement...

full text

Treating C3 glomerulopathy with eculizumab

BACKGROUND C3 glomerulopathy (C3G) is a rare, but severe glomerular disease with grim prognosis. The complex pathogenesis is just unfolding, and involves acquired as well as inherited dysregulation of the alternative pathway of the complement cascade. Currently, there is no established therapy. Treatment with the C5 complement inhibitor eculizumab may be a therapeutic option. However, due to ra...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 25  issue 133

pages  340- 345

publication date 2016-02

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

No Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023